Ginkgo Bioworks acquires struggling synbio rival Zymergen in $300M all-stock deal
Ginkgo Bioworks is picking up a synthetic biology competitor in what it says is its largest M&A deal yet.
Ginkgo put out word early Monday it is acquiring Zymergen in an all-stock deal, valuing the Emeryville, CA-based synthetic biology biotech at around $300 million. The deal has been approved by both companies’ board of directors, and is slated to close sometime in the first quarter next year. Once done, Zymergen shareholders will own approximately 5.25% of the combined company.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.